Iron Infusion Monitoring Guide

Home› Clinicians› IV iron monitoring
🩸
IV Iron — Post-Infusion Monitoring Protocol
When to recheck, what constitutes a response, non-response workup, condition-specific intervals, and referral triggers. For GPs and registrars.
Clinicians AU AusPrescr · RCPA · KHA-CARI
📋 Sources: Patel S. “Ferric carboxymaltose: A practical guide on the administration of iron infusions in general practice.” AJGP 2025;54(5). doi: 10.31128/AJGP-07-24-7354. Note: erratum published September 2025 — verify at racgp.org.au/ajgp. Lucas S, Garg M. “Intravenous iron: An update.” Intern Med J 2024;54(1):26–34. doi: 10.1111/imj.16184 — Hb rise 20–30 g/L within 8 weeks reported in studies. Pasricha S et al. “Correcting iron deficiency.” Australian Prescriber 2010;33:38–44 (PMC5155066) — peak ferritin and Hb response timing. RCPA Iron Studies Standardised Reporting Protocol, 2nd ed., November 2021 (review date November 2025 — check for updated edition at rcpa.edu.au) — states: “the ferritin level can remain elevated for 2–3 months after intravenous iron infusion.” Ferritin cut-off: <30 µg/L diagnostic of iron deficiency in adults. SA Health BloodSafe Iron Deficiency Management Checklist for GPs, last updated 14 August 2024 — sahealth.sa.gov.au. National Blood Authority Australia. Iron product choice and dose calculation for adults, March 2016 — blood.gov.au. Brisbane South HealthPathways: Iron deficiency — intravenous iron infusion, 2022. KHA-CARI Anaemia of CKD Guidelines — cari.org.au. KDIGO Anaemia Guideline 2024. ECCO Iron Deficiency in IBD Consensus 2022. ESC Heart Failure Guidelines 2021. ⚠️ Tier 2 — use clinical judgement. The Hb response threshold used on this page (≥10 g/L) should be verified against the AJGP 2025 article which cites 20–30 g/L in 8 weeks from some studies. This page is a decision-support reference only — clinical judgement and local protocols take precedence.
⚠️ Tier 2 — Clinician review pending. Thresholds and monitoring intervals on this page are sourced from published guidelines (Australian Prescriber, RCPA, KHA-CARI, KDIGO, ECCO, ESC) but have not yet been reviewed by the AskMyGP clinical editor. Verify specific thresholds against current guideline versions before clinical use. Always apply clinical judgement and local protocols.

Standard post-infusion monitoring

Ferritin peaks at 7–9 days and remains unreliable for up to 4 weeks due to infusion-related elevation independent of true stores. AusPrescr 2010 TSAT may be elevated for up to 2 weeks. The RCPA states ferritin "can remain elevated for 2–3 months after intravenous iron infusion." RCPA 2021

Timing Tests Rationale
Within 1–2 weeks
Optional early check		 FBC only (Hb, reticulocytes if available) Reticulocyte peak at day 5–10 confirms marrow response. Hb begins rising. Do not check iron studies — ferritin is unreliable. RCPA 2021 AusPrescr 2010
Standard
4–8 weeks 		FBC + iron studies
(ferritin + TSAT ± CRP)		 Primary monitoring window. Ferritin reflects true stores. Confirm Hb response. Add CRP if inflammatory condition — ferritin is an acute-phase reactant. AJGP 2025 SA Health 2024
Optimal
3 months
for doses ≥1000mg 		FBC + iron studies Most accurate assessment after large-dose infusions (Ferinject 1000mg, Monofer 1000–1500mg). Iron distribution continues for up to 12 weeks. RCPA 2021 AJGP 2025
Ongoing
Every 3–6 months 		FBC + iron studies Patients with ongoing losses (HMB, IBD, CKD). Interval depends on degree of loss and stability. See condition-specific table below. KHA-CARI ECCO 2022
Defining adequate response at 4–8 weeks
✓ Adequate response
Hb rise ≥10 g/L from baseline ⚠️ verify — see note
Ferritin ≥50 µg/L (some guidelines target ≥100) SA Health 2024
TSAT ≥20% RCPA 2021
Symptom improvement consistent with response
✗ Inadequate response
Hb rise <10 g/L at 4–8 weeks ⚠️ verify — see note
Ferritin remains <30 µg/L at 8 weeks RCPA 2021
Persistent symptoms despite biochemical improvement
Hb falls after initial rise (ongoing loss)
ℹ️
Ferritin target: RCPA defines <30 µg/L as diagnostic of iron deficiency in adults. RCPA 2021 Most Australian sources use ≥50 µg/L as minimum repletion target; many clinicians aim for ≥100 µg/L for patients with ongoing losses. SA Health 2024 Note on Hb threshold: The AJGP 2025 article cites Hb rise of 20–30 g/L within 8 weeks from study data; AJGP 2025 the ≥10 g/L figure used above as the minimum response threshold requires clinical review before this page is Tier 1. ⚠️ Tier 2
Non-response — differential and workup

If Hb has not risen ≥10 g/L or ferritin remains low at 4–8 weeks, consider:

🩸
Ongoing blood loss not addressed — the most common reason. Has the underlying cause been investigated and treated? Heavy menstrual bleeding, occult GI blood loss (exclude in men and post-menopausal women — colonoscopy/gastroscopy), coeliac disease, post-bariatric malabsorption.
🔥
Anaemia of chronic disease / functional iron deficiency — elevated CRP with low TSAT despite adequate ferritin. Ferritin may be falsely elevated by inflammation. Request CRP alongside iron studies. True iron deficiency can coexist with inflammatory anaemia.
🧬
Haemoglobinopathy — thalassaemia trait can present with microcytic anaemia mimicking IDA. Check Hb electrophoresis / HPLC if MCV remains low with replete iron stores, or if there is a relevant family history or ethnicity.
💊
B12 / folate deficiency — a concurrent macrocytic process can mask a mixed deficiency. MCV may appear normal. Check B12 and folate if not recently tested, particularly in older patients, vegans, or patients on metformin or PPIs.
🫀
Renal or cardiac cause — CKD-related erythropoietin deficiency, cardiac failure with hepcidin upregulation. Functional iron deficiency despite replete stores. Refer to nephrology or cardiology if suspected.
🔬
Inadequate dose — was the Ganzoni-calculated total dose given? Review dose calculation. Consider repeat infusion if stores remain depleted and cause of ongoing loss is controlled.
Condition-specific monitoring intervals
Condition Initial recheck Ongoing Notes / Guideline
Iron deficiency (no ongoing loss)
e.g. post-pregnancy, diet		 4–8 weeks 6–12 monthly if stable
until cause resolved		 Investigate cause. Once stores replete and cause addressed, annual check adequate. AusPrescr 2010 SA Health 2024
Heavy menstrual bleeding 4–8 weeks Every 3–6 months
while bleeding persists		 Recurrence common without treating underlying cause. Consider gynaecology referral. Target ferritin ≥50, consider ≥100. SA Health 2024 AJGP 2025
Inflammatory bowel disease
(Crohn’s, UC)		 4–8 weeks Every 3 months (active disease)
Every 6–12 months (remission)		 Active disease increases hepcidin — functional iron deficiency common. CRP essential for interpreting ferritin. Target ferritin 100–300 µg/L. ECCO 2022
CKD (not on dialysis) 4–8 weeks Every 3 months Monitor TSAT and ferritin 3-monthly. Target TSAT 20–50%, ferritin 100–500 µg/L. Avoid if TSAT >50% or ferritin >800 µg/L. KHA-CARI KDIGO 2024
CKD on haemodialysis Monthly during
initiation phase		 Every 3 months
once stable		 Iron sucrose PBS-restricted to this indication. Check TSAT and ferritin monthly during initiation; 3-monthly when stable on ESA therapy. KDIGO 2024
Heart failure 4–8 weeks Every 3–6 months IV iron for NYHA II–III HF with TSAT <20% or ferritin <100 µg/L (or 100–299 with TSAT <20%). Repeat when ferritin drops below threshold. ESC 2021 CONFIRM-HF
Pregnancy 2–4 weeks post-infusion
(Hb check)		 Per obstetric care plan From 2nd trimester only (≥16 weeks). Recheck FBC 2–4 weeks; iron studies at 4–8 weeks. Target Hb ≥110 g/L. Liaise with obstetric team. AJGP 2025 RANZCOG
Pre-operative anaemia correction 2–4 weeks post-infusion
or pre-op assessment		 Single episode — post-op check if indicated Hb rise expected within 2–4 weeks. Recheck FBC before surgery to confirm response. If time insufficient, plan for transfusion. AJGP 2025
Ferritin interpretation — key pitfalls
⚠️ Ferritin is an acute-phase reactant. RCPA 2021 Elevated in infection, active inflammation, liver disease, malignancy, and haemochromatosis — independently of iron stores. A "normal" or elevated ferritin does not exclude iron deficiency in an inflamed patient. Always interpret with CRP.
⚠️ TSAT is the more reliable functional marker in inflammatory states. RCPA 2021 AJGP 2025 TSAT <20% with ferritin that looks normal (but CRP elevated) suggests functional iron deficiency or true deficiency masked by inflammation.
⚠️ Post-infusion ferritin elevation. Ferritin remains unreliable for up to 4 weeks post-infusion RCPA 2021 and "can remain elevated for 2–3 months." RCPA 2021 Testing too early is the most common error.
⚠️ Very high ferritin post-infusion (>500 µg/L at 4 weeks). Likely residual infusion effect or coexisting inflammation. RCPA 2021 Check CRP. Repeat at 8–12 weeks before acting on the result. True iatrogenic iron overload from a single therapeutic infusion is uncommon.
Post-infusion prescribing reminders
Oral iron — withhold AJGP 2025
Withhold for at least 5 days post-infusion (some recommend up to 1 week). No additive benefit; may cause GI side effects. Restart based on follow-up results if deficiency recurs.
Delayed reactions — NSAIDs AJGP 2025
Arthralgias, myalgias, fever within 24–72 hours are self-limiting. Paracetamol first-line; NSAIDs acceptable if no contraindications and reaction is not anaphylactic.
MRI — timing AJGP 2025
Monofer (ferric derisomaltose): wait ≥1 month before MRI. Ferinject (ferric carboxymaltose): wait ≥1 week. Document infusion date clearly in the referral.
Hypophosphataemia — Ferinject AJGP 2025
FGF23-mediated phosphaturia specific to ferric carboxymaltose. Check phosphate if symptomatic (fatigue, bone pain, proximal weakness) or after repeated infusions — especially malabsorption, osteomalacia.
Referral triggers
🔴
Haematology: IDA in a man or post-menopausal woman without identified cause — exclude GI malignancy. RCPA 2021 Recurrent IDA despite adequate treatment. Hb <70 g/L with rapid decline. Suspected haemoglobinopathy or haematological malignancy.
🔴
Gastroenterology / Colorectal: Unexplained IDA in men or post-menopausal women — bidirectional endoscopy. RCPA 2021 AJGP 2025 Coeliac serology positive. Suspected IBD not yet diagnosed.
🟡
Nephrology: CKD with IDA not responding to IV iron, or requiring ongoing monthly dosing. eGFR <30 with iron deficiency — nephrology manages ESA and iron co-therapy. KHA-CARI KDIGO 2024
🟡
Cardiology / HF clinic: Heart failure with iron deficiency (TSAT <20% or ferritin <100 µg/L) — IV iron improves functional capacity and QoL. ESC 2021 CONFIRM-HF AFFIRM-AHF
🟡
Gynaecology: Heavy menstrual bleeding requiring recurrent iron infusions without definitive management of the underlying cause. AJGP 2025
📋
Patient version of this guide
Plain-English explanation of when to recheck and what to expect — share with patients after their infusion.
Patient guide →
Related tools
💉
IV Iron Dose Calculator
Ferinject & Monofer — Ganzoni & simplified
⚗️
eGFR Calculator
CKD staging for iron dosing decisions
📊
Normal Lab Values
Ferritin, Hb, TSAT reference ranges
📋
Investigation Frequency
Monitoring intervals by condition
💡
Migraine Infusion Prescribing
PBS Authority, billing & setup for practices already doing IV iron
💓
Heart Failure Management
IV iron criteria in HFrEF (ferritin <100 or 100–299 with TSat <20%)
🫘
CKD Management Reference
IV iron in CKD: ferritin thresholds, SGLT2i overlap, monitoring intervals
🧪 Pathology reference: Iron studies — Pathology Tests Explained (RCPA) ↗